{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:37:06Z","timestamp":1772879826440,"version":"3.50.1"},"reference-count":31,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2017.4193","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T10:53:00Z","timestamp":1510051980000},"source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine"],"prefix":"10.3892","author":[{"given":"Kai","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhi","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Nikfarjam","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3048, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"key20200713184414_b1-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20200713184414_b2-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"key20200713184414_b3-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-015-0025-y","article-title":"Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity","volume":"4","author":"Zhang","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"key20200713184414_b4-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"key20200713184414_b5-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1053\/j.gastro.2012.12.042","article-title":"Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma","volume":"144","author":"Zheng","year":"2013","journal-title":"Gastroenterology"},{"key":"key20200713184414_b6-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbamcr.2012.10.015","article-title":"p21-activated kinases and gastrointestinal cancer","volume":"1833","author":"He","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"key20200713184414_b7-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-016-2057-z","article-title":"FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine","volume":"16","author":"Yeo","year":"2016","journal-title":"BMC Cancer"},{"key":"key20200713184414_b8-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"8778","DOI":"10.18632\/oncotarget.2398","article-title":"p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT- and ERK-dependent activation of NF-\u03baB pathway","volume":"5","author":"Tyagi","year":"2014","journal-title":"Oncotarget"},{"key":"key20200713184414_b9-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.canlet.2015.10.028","article-title":"p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling","volume":"370","author":"Tyagi","year":"2016","journal-title":"Cancer Lett"},{"key":"key20200713184414_b10-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4143\/crt.2014.054","article-title":"p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines","volume":"47","author":"Moon","year":"2015","journal-title":"Cancer Res Treat"},{"key":"key20200713184414_b11-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"key20200713184414_b12-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"9446","DOI":"10.1073\/pnas.0911863107","article-title":"Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth","volume":"107","author":"Murray","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200713184414_b13-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbamcr.2010.05.007","article-title":"p21-activated kinase 1 stimulates colon cancer cell growth and migration\/invasion via ERK- and AKT-dependent pathways","volume":"1803","author":"Huynh","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"key20200713184414_b14-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.canlet.2014.01.001","article-title":"Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases","volume":"346","author":"Yeo","year":"2014","journal-title":"Cancer Lett"},{"key":"key20200713184414_b15-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/2159-8290.CD-12-0541","article-title":"GSK-3\u03b1 promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-\u03baB","volume":"3","author":"Bang","year":"2013","journal-title":"Cancer Discov"},{"key":"key20200713184414_b16-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/08941939.2013.797057","article-title":"Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma","volume":"26","author":"Nikfarjam","year":"2013","journal-title":"J Invest Surg"},{"key":"key20200713184414_b17-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"key20200713184414_b18-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coi.2016.06.006","article-title":"High-throughput genomic profiling of tumor-infiltrating leukocytes","volume":"41","author":"Newman","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"key20200713184414_b19-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour microenvironment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"key20200713184414_b20-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"key20200713184414_b21-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.acr.2015.05.001","article-title":"Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment","volume":"128","author":"Peske","year":"2015","journal-title":"Adv Cancer Res"},{"key":"key20200713184414_b22-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","article-title":"Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors","volume":"73","author":"Rusakiewicz","year":"2013","journal-title":"Cancer Res"},{"key":"key20200713184414_b23-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ctrv.2013.11.005","article-title":"Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies","volume":"40","author":"Sideras","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"key20200713184414_b24-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br J Cancer"},{"key":"key20200713184414_b25-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"key20200713184414_b26-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"key20200713184414_b27-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"key":"key20200713184414_b28-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"e96565","DOI":"10.1371\/journal.pone.0096565","article-title":"Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment","volume":"9","author":"Shibuya","year":"2014","journal-title":"PLoS One"},{"key":"key20200713184414_b29-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","article-title":"Current and emerging therapies in metastatic pancreatic cancer","volume":"23","author":"Manji","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20200713184414_b30-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713184414_b31-ijo-52-01-0261","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T18:56:09Z","timestamp":1594666569000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2017.4193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":31,"URL":"https:\/\/doi.org\/10.3892\/ijo.2017.4193","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]}}}